Hoffmann P, et al. - Given that vedolizumab was approved for the therapy of ulcerative colitis and Crohn’s disease in mid-2014, researchers intended to determine the real-world treatment data for a balanced assessment of its position among other therapeutic options. Based on electronic medical records, study participants with ulcerative colitis or Crohn’s disease, starting vedolizumab therapy at the outpatient clinic for inflammatory bowel diseases at the University Hospital ­Heidelberg between June 1, 2014, and August 31, 2016, were enrolled. They observed that vedolizumab was effective in achieving the response in a relatively treatment-refractory cohort of inflammatory bowel disease patients. It was noted that the majority of the patients were not satisfactorily treated, as they did not reach remission.